tbuckley/cabot-search huggingface dataset:
Rectal dose-volume differences for scanning proton beam therapy with or without an endorectal balloon for the treatment of prostate cancer.
Authors: Anand Desai, Joshua B. Stoker, Cody A. Wages, X. Ron Zhu, Andrew Lee
Journal: Journal of Clinical Oncology (2013)

243 Background: Endorectal balloons (ERB) are routinely used in proton radiation for prostate cancer (PCa). The dosimetric implications, however, in conjunction with scanning proton beam therapy (SPT) have not been studied. We sought to describe dose-volume values with the use of an ERB vs no ERB for SPT for PCa. Methods: We analyzed 10 patients with localized PCa. Each patient underwent two CT simulations, one with a water-filled ERB (50-60 ml) and one with no ERB. For 8 patients, the prostate and proximal 1 cm of the seminal vesicles was the clinical target volume (CTV), with the prostate only as CTV for 2 patients. We defined 3 structures: rectum (R), anterior rectal wall (ARW) as a 3 mm rim of the anterior half of the rectum, and AR-CTV as the ARW only on slices with a contoured CTV. SPT plans were created in both cases for each patient, with the creation of a scanning target volume (STV), which expanded the CTV by 6 mm in all dimensions except 4 mm posteriorly and 12 mm laterally. Two opposed lateral beams were used to plan to the STV. Total dose was 78 Co-60 Gy equivalent in 39 fractions, to cover 95% of the STV. RBE was 1.1. We compared the dose-volume values for the R, ARW, and AR-CTV between the two arms. Results: The ERB significantly increased the R volume for all cases (61 ± 11 ml vs 105 ± 10 ml (p&lt;0.01)). Rectal volumes radiated for all cases: V10, 55%; V50, 23%; and V70, 11%. The ERB significantly decreased the R volume radiated for all dose levels V5-V82 (p&lt;0.05). The absolute difference was larger at low dose levels (8% at V10) and intermediate dose levels (5% at V50) compared to high dose levels (3% at V70). For the ARW, the ERB did not significantly change the volume radiated at any dose level. For the AR-CTV, the ERB significantly decreased the volume radiated for dose levels V20-V60 (p&lt;0.05). Conclusions: The ERB provided a significant decrease in R volume radiated at all dose levels, and significantly decreased the AR-CTV volume, which represents a high risk volume, radiated at intermediate dose levels. Rectal doses with SPT, however, were low whether using an ERB or not. In the setting of the low rectal doses delivered, further study regarding the clinical benefit is warranted.
Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.
Authors: Rentian Feng, Xiangao Huang, Les Coulton, Hendrik De Raeve, Maurizio DiLiberto, Scott Ely, Guozhi Xiao, Min Luo, Eline Menu, Peter Croucher, G. David Roodman, Karin Vanderkerken, Selina Chen-Kiang, Suzanne Lentzsch
Journal: Blood (2009)
Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.
Authors: Tayfun Ozcelik, Varsha Vakil, Eric Smith, Marc Braunstein, Justin Maroney, Uwe Klueppelberg, Sevgi Bagislar, Cemaliye Akyerli, Olcay Batuman
Journal: Blood (2004)
Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.
Authors: Koichi Takahashi, Mariela Sivina, Yasuhiro Oki, Luis E Fayad, Sattva S. Neelapu, Larry W. Kwak, Lianchun Xiao, Xuelin Huang, Kai Fu, Wing Chung Chan, Julie M Vose, Hagop M. Kantarjian, Michael Keating, Jan A. Burger
Journal: Blood (2012)
Trusts move to new contract as BMA vows to keep fighting imposition
Authors: Abi Rimmer, Susan Mayor
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Trusts move to new contract as BMA vows to keep fighting imposition Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning
Authors: Jan J Cornelissen, Alois Gratwohl, Kees GM van Montfort, Thomas Pabst, Johan Maertens, H. Berna Beverloo, Marinus van Marwijk Kooy, P.W. Wijermans, Bart J Biemond, Dimitri A. Breems, Edo Vellenga, Leo F Verdonck, Martin F. Fey, Mojca Lavrencic, Jeroen JWM Janssen, Gerwin Huls, Jurgen Kuball, Jakob R. Passweg, Carlos Graux, Harry C. Schouten, Gert Ossenkoppele, Bob Lowenberg
Journal: Blood (2011)
A Public Health Framework for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry
Authors: Rachel Ann Barry, Stanton Glantz
Journal: PLoS Medicine (2016)

Points• The US states that have legalized retail marijuana are using US alcohol policies as a model for regulating retail marijuana, which prioritizes business interests over public health.• The history of major multinational corporations using aggressive marketing strategies to increase and sustain tobacco and alcohol use illustrates the risks of corporate domination of a legalized marijuana market.• To protect public health, marijuana should be treated like tobacco, not as the US treats alcohol: legal but subject to a robust demand reduction program modeled on successful evidence-based tobacco control programs.• Because marijuana is illegal in most places, jurisdictions worldwide (including other US states) considering legalization can learn from the US experience to shape regulations that prioritize public health over profits.
Therapy Response by Decrease of Free Light Chain Concentration in Multiple Myeloma Patients Treated with Bortezomib/Doxorubicin/Dexamethasone as First-Line Therapy.
Authors: Wilma Zinke-Cerwenka, Tatjana Stojakovic, Hubert Scharnagl, Sabine Wassertheurer, Werner Linkesch
Journal: Blood (2007)
Recurrent spinal cord glioblastoma: Salvage therapy with bevacizumab.
Authors: S. K. Johnston, M. C. Chamberlain
Journal: Journal of Clinical Oncology (2010)

e12501 Background: Primary spinal cord tumors constitute 2%-4% of all primary CNS malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Methods: 6 patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ration and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after 1 cycle of therapy and thereafter following every 2 cycles of bevacizumab. Results: Treatment-related complications included fatigue in 6 patients, constipation in 4, hypertension in 2, thrombophlebitis in 2, and infection without neutropenia in 2. There were 3 grade 3 toxicities (1 each fatigue, leukopenia and thrombophlebitis). There were no treatment-related deaths. After one cycle of bevacizumab, 1 patient (17%) demonstrated progressive disease, 2 (34%) partial responses and 3 (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Conclusions: Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma. No significant financial relationships to disclose.
A Randomized Multicenter Clinical Trial of Ultrathin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) versus DSAEK
Authors: Mor M. Dickman, Pieter J. Kruit, Lies Remeijer, Jeroen van Rooij, Allegonda Van der Lelij, Robert H.J. Wijdh, Frank J.H.M. van den Biggelaar, Tos T.J.M. Berendschot, Rudy M.M.A. Nuijts
Journal: Ophthalmology (2016)
A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker
Authors: Anna Stengel, Wolfgang Kern, Melanie Zenger, Karolina Perglerová, Susanne Schnittger, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2014)
Prospective, multicentric cohort study of surgery and radiotherapy with concomitant and adjuvant chemotherapy (temozolomide; TMZ) for patients with newly diagnosed and glioblastoma multiforme.
Authors: W. Stummer, T. Meinel, P. Martus
Journal: Journal of Clinical Oncology (2010)

e12534 Background: It is generally accepted that maximum resection is beneficial in patients with glioblastoma treated by adjuvant radiotherapy. However, reliable data on the value of cytoreductive surgery in conjunction with adjuvant concomitant radiochemotherapy are unavailable. It may be that concomitant radiochemotherapy abolishes the need for extensive surgical cytoreduction. We have therefore performed a cohort study of patients treated by surgery and concomitant radiochemotherapy with no or small residual tumor to test for differences in outcome. Methods: 180 patients with newly diagnosed and operated glioblastoma multforme, Karnofsky Performance Score ≥ 70 %, and early post-op. MRI (< 72 hours) demonstrating no or small residual contrast-enhancing tumor (< 1.5 cm) were planned for this prospective, multicenter cohort study. Primary aims were progression-free survival, secondary aims overall survival and safety. Results: Of 143 patients with evaluable early MRI and adjuvant concomitant temozomoide 75 patients had no residual tumor, 32 patients small residual tumor (0-1.5 cm diameter) and 59 patients larger residual tumor > 1.5 cm diameter (average 1.9 ± 1.2 cm), who did not fulfill the entry criteria regarding residual tumor diameter. PFS in patients with complete resection vs. small and larger residual tumors was 14.4 (16.0- 21.3) months, compared to 9.03 (3.04-15.0) and 5.33 (2.86-7.8, p < 0.0001). Median overall survival was not reached in patients with complete resections (95% CI: 21.4-25.9), as opposed to 16.9 (13.3-21.5) or 13.9 (10.3-17.5, p < 0.0001) months. Cox analysis demonstrated degree of resection (HR 1.84, p = 0.001) and age (1.03, p = 0.05) to be the only independent factors affecting survival. Conclusions: Even small residual contrast-enhancing tumor loads in patients with surgery for glioblastoma affect the efficacy of adjuvant concomitant radiochemotherapy in glioblastoma multiforme. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Essex Pharma
Clinical Significance of Polymorphisms During Hepatopoietic Stem Cell Transplantation.
Authors: Jae-Sook Ahn, Hee Nam Kim, Nan Young Kim, Yu– Li, Il-Kwon Lee, Yeo-Kyeoung Kim, Soo-Young Bae, Deok-Hwan Yang, Je-Jung Lee, Hyeoung Joon Kim
Journal: Blood (2010)
Abstract 5189: Inhibitory effect of phytochemicals on oncostatin-M-induced tumor invasion and migration in human esophageal carcinoma
Authors: Eijin Naka, Yuko Takahashi, Hisahiro Matsubara, Kazunori Kato
Journal: Cancer Research (2015)

Abstract An epithelial-to-mesenchymal transition (EMT) is one of important phenomenon in tumor metastasis. Oncostatin-M (OSM) belonging to the IL-6 family is a cytokine that participates in invasion and migration of various cancer cells. It is produced by macrophage and stimulates the JAK/STAT signal transduction pathway. In this study, we examined the effect of OSM on EMT of human esophageal carcinoma cells and found a way to inhibit cell metastasis. We first observed morphological changes of tumor cells from an epithelial-like phenotype to a more spindle-shaped, mesenchymal phenotype by OSM. Consistent with these findings, OSM also promoted cell motility using a wound scratch assay and matrigel invasion assay. Moreover, we observed that intracellular stat3 phosphorylation was promoted by the stimulation of OSM by Western blotting. To confirm the contribution of p-stat3, we used a selective JAK2/STAT3 inhibitor cucurbitacin I. As a result, cucurbitacin I strongly inhibited OSM-induced tumor cell invasion and migration. Then, we used two dietary phytochemical resveratrol (polyphenol in grapes) and sulforaphane (isothiocyanate in broccolis), both were reported as candidates of stat3 inhibitor. By the addition of resveratrol or sulforaphane, we found that these markedly inhibited OSM-induced stat3 phosphorylation, the expression of EMT-related genes (snail, slug and vimentin) and tumor cell migration. Overall, our findings provide new evidence that these phytochemicals suppress OSM-induced tumor invasion and migration through inhibiting stat3 phosphorylation and EMT pathway. Citation Format: Eijin Naka, Yuko Takahashi, Hisahiro Matsubara, Kazunori Kato. Inhibitory effect of phytochemicals on oncostatin-M-induced tumor invasion and migration in human esophageal carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5189. doi:10.1158/1538-7445.AM2015-5189
Socio-economic inequalities in stage at diagnosis, and in time intervals on the lung cancer pathway from first symptom to treatment: systematic review and meta-analysis
Authors: Lynne F Forrest, Sarah Sowden, Greg Rubin, Martin White, Jean Adams
Journal: Thorax (2016)

Cancer diagnosis at an early stage increases the chance of curative treatment and of survival. It has been suggested that delays on the pathway from first symptom to diagnosis and treatment may be socio-economically patterned, and contribute to socio-economic differences in receipt of treatment and in cancer survival. This review aimed to assess the published evidence for socio-economic inequalities in stage at diagnosis of lung cancer, and in the length of time spent on the lung cancer pathway. MEDLINE, EMBASE and CINAHL databases were searched to locate cohort studies of adults with a primary diagnosis of lung cancer, where the outcome was stage at diagnosis or the length of time spent within an interval on the care pathway, or a suitable proxy measure, analysed according to a measure of socio-economic position. Meta-analysis was undertaken when there were studies available with suitable data. Of the 461 records screened, 39 papers were included in the review (20 from the UK) and seven in a final meta-analysis for stage at diagnosis. There was no evidence of socio-economic inequalities in late stage at diagnosis in the most, compared with the least, deprived group (OR=1.04, 95% CI=0.92 to 1.19). No socio-economic inequalities in the patient interval or in time from diagnosis to treatment were found. Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor for survival inequalities in cancer. However, socio-economic inequalities in stage at diagnosis were not found in a meta-analysis for lung cancer. <h3>PROSPERO protocol registration number</h3> CRD42014007145.
Axillary web syndrome among breast cancer patients who underwent axillary dissection: incidence and predictive factors.
Authors: Luiz Felipe Nevola Teixeira, Federica Baggi, Fabio Sandrin, Maria Claudia Simoncini, Emilio Bonacossa, Patrizia Dadda, Michele Sciotto Marotta, Gabriella Lanni, Andre Deeke Sasse, Sara Gandini, Paolo Veronesi, Alberto Luini
Journal: Journal of Clinical Oncology (2015)

e20728 Background: Axillary Web Syndrome (AWS) is a commonly diagnosed sequela after breast cancer axillary surgery, characterized by fibrotic cords located on the operated arm. Symptoms are disabling, causing pain and reduction of arm range of motion during daily activities. In recent years, specialists in the field of breast cancer rehabilitation have taught both professionals and patients about its correct diagnosis, onset, evaluation over time and treatment, but there is still a lack of information and studies about this topic. The main objectives of our study are to estimate the incidence of AWS and to investigate possible predictive factors, regarding onset, timing of resolution and response to the treatment. Methods: With the approval of the European Institute of Oncology (IEO) ethical committee, we developed a new validated questionnaire to provide information about the syndrome and help in self-diagnosis. Patients who underwent axillary dissection were enrolled in a prospective cohort study. To assess the disease status we used a validated screening test questionnaire (ST-AWS) created by our physiotherapy staff. Patients were evaluated by telephone interview at 2 weeks, 4 weeks and 8 weeks after surgery. Results: From July 2013 to July 2014, 370 breast cancer patients were enrolled. Median age was 50 years. AWS incidence was 51% with 94% onset in the first 4 weeks after surgery; 42% of the patients did not recover in the first 8 weeks. Higher educational level (p < 000.1), lower body mass index (BMI) (p < 0.001) and younger age (p = 0.001) were found to be significantly associated with positive self-diagnosis of AWS. Conclusions: Our findings indicated that the incidence of AWS is high in axillary dissection patients, particularly in the first month after surgery. Not all patients achieved recovery during our 8 weeks follow-up, suggesting that assessment and treatment should be longer. Moreover older patients, with high BMI and lower educational level should be accurately evaluated. There still a lack of information about AWS management and treatment and we found that some patients report recurrence after adjuvant treatments. Additional studies are warranted to confirm these results.
Clinical evaluation of a novel surgical probe designed for PET radio-isotopes (PET-Probe) in patients with metastatic melanoma
Authors: S. A. Gulec, F. Daghighian, L. Foshag, K. Edwards, R. Essner
Journal: Journal of Clinical Oncology (2004)

7521 Background: Survival of stage IV melanoma patients with limited number and sites of metastases can be improved with surgical treatment in combination with immunotherapy or biologic therapy. FDG-PET imaging plays an integral role in the selection of patients who may benefit from surgery. However, its detection sensitivity is less than optimal for lesions under one cm, and the surgical exposure of image-positive lesions could be challenging. Methods: We developed a hand-held radiation detection probe system (PET-Probe, IntraMedical Imaging LLC, LA, CA for intraoperative localization of PET-positive solid tumors. 26 patients with metastatic melanoma (6F, 20M, ages 31–78) were studied prospectively. All patients underwent preoperative PET, CT and/or MR imaging for evaluation for recurrent or metastatic disease. Patients underwent surgical exploration employing the PET-Probe 1 to 4 hours after injection of 10 mCi (FDG) on the day of surgery. Results: The PET-Probe detected all FDG-PET image-positive lesions. Lesions were in the neck and supraclavicular (n=4), axilla (n=2), groin and deep iliac (n=2), trunk and extremity subcutaneous tissue (n=3), abdominal and retroperitoneal (n=13) and lung (n=2). Smallest detectable lesion was 0.5cm. In 4 cases (15%), PET-Probe identified lesions that were not seen on PET images. In 3 cases (12%), PET-Probe detected surgically non-palpable or visible lesions, two of which were under one cm. Over-all, in 7/26 (27%) patients, PET-Probe findings improved intraoperative management by localizing the lesion in an anatomically difficult location, by identifying a lesion outside the planned resection limits or identifying residual disease post-resection. The success of hot spot identification was affected by the anatomic location of the lesions and high background activity in head and neck region and chest due to physiologic FDG uptake in the brain and heart. Conclusions: The PET-Probe facilitated identification of occult tumor masses and lesions at difficult locations. PET probe may become a useful adjunct for the intraoperative evaluation of patients with metastatic melanoma. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Intramedical Imaging, LLC Intramedical Imaging, LLC Intramedical Imaging, LLC
In Vitro and In Vivo Evidence That Umbilical Cord Blood (UCB)-Derived CD45-/SSEA-4+/OCT-4+/CD133+/CXCR4+/Lin- Very Small Embryonic/Epiblast Like Stem Cells (VSELs) Do Not Contain Clonogenic Hematopoietic Progenitors but Are Highly Enriched in More Primitive Stem Cells - Novel View On Hierarchy of UCB Stem Cell Compartment.
Authors: Ewa K. Zuba-Surma, Izabela Klich, Marcin Wysoczynski, Nicholas J Greco, Mary J. Laughlin, Mariusz Z Ratajczak, Janina Ratajczak
Journal: Blood (2009)
Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study.
Authors: S. L. Cohn, S. Bhatia, W. B. London, P. W. Mcgrady, C. Crotty, C. Sun, T. O. Henderson
Journal: Journal of Clinical Oncology (2010)

9517 Background: The role of race and ethnicity in disease presentation and survival among children with NBL remains unclear. We investigated the relationship between race/ethnicity, NBL biology, and outcome using data from the COG NBL biology protocol ANBL00B1. Methods: Disease presentation and survival probabilities were compared among white, black, Hispanic, Asian, and Native American children. Analysis of disease outcome was measured as overall (OS) and event-free survival (EFS), and was adjusted for prognostic clinical features and disease biology. Results: 3,923 children with NBL enrolled between 2001 and 2009 were included. Non-hispanic whites ("white") constituted 73% of the cohort; 11% were Hispanic, 11% non-hispanic black ("black"), 4% Asian, and 1% Native-American. When compared with whites, blacks and Native-Americans were more likely to present with high-risk disease (blacks: 56% vs. 43%, p<0.001, Native-American: 66% vs. 43%, p=0.04). The prevalence of high-risk disease among Asian and Hispanic children did not differ from whites. Three-year EFS was: Hispanics, 74%, whites, 69%, blacks, 63%, Asians, 62%, and Native- Americans, 38%, (p<0.001). Although univariate analysis revealed worse EFS for blacks (HR 1.28; p=0.01) and Native-Americans (HR 2.33; p=0.003), when compared with whites, adjustment for risk group abrogated these differences. However, examination of EFS by follow-up time (<2 years vs. 2+ years from diagnosis) revealed a higher prevalence of late-occurring events among blacks as compared with whites. This was confirmed in the multivariate analyses restricted to 2+ year survivors, where blacks had significantly worse EFS (HR=1.5, p=0.04) as compared with whites. Conclusions: Black and Native-American children are more likely to present with high-risk NBL. Blacks demonstrate a propensity for delayed events, causing a divergence in EFS with follow-up from diagnosis. Studies are being planned to delineate the role of genetic predisposition in the racial differences in prevalence of high risk NBL, as well as survival outcomes. No significant financial relationships to disclose.
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.
Authors: Maria-Victoria Mateos, Lucía López-Corral, Miguel T Hernández, Javier de la Rubia, Juan José Lahuerta, Pilar Giraldo, Joan Bargay, Laura Rosiñol, Albert Oriol, Jose García-Laraña, Luis Palomera, Felipe de Arriba, Felipe Prosper, Mariluz Martino, Ana-Isabel Teruel, José Hernández, Graça Esteves, Mario Mariz, Adrian Alegre, J.L. Guzmán, Nuria Quintana, Jose-Luis Garcia, Jesús F. San-Miguel
Journal: Blood (2009)